Skip to content

COVID-19 Resources and Updates

Keep up to date on the latest from CBCRP, RGPO, and UC related to the COVID-19 pandemic.

During the coronavirus pandemic, CBCRP has three priorities: the safety and well-being of our workforce, the continuation of our business as a funder of impactful breast cancer research and the support of our research community. This page provides resources to help support our investigators.

  • RGPO Grantee Guidelines During COVID-19 Pandemic
  • COVID-19 News and Updates from UC
  • Emergency COVID-19 Research Seed Funding with Option of Continuation Funding (opportunity now closed)

RGPO Grantee Guidelines During COVID-19 Pandemic

We recognize that many research projects, institutions, faculty, and trainees are adjusting to new work and personal circumstances due to the COVID-19 pandemic, and we want to extend our support to everyone affected. To ensure our grantees have flexibility over the next few months, RGPO has issued special guidelines related to reporting and research continuity:

Communication to Grantees About COVID-19

Stay up to date with on our latest grant administration policies and resources at the RGPO Grant Administration webpage.

COVID-19 News and Updates from UC 

Please see the website for UC Research & Innovation for news and updates on COVID-19 affecting research at the University of California. Please see the University of California Coronavirus webpage for additional COVID-19 news and updates affecting UC.

Emergency COVID-19 Research Seed Funding with Option of Continuation Funding

Update: This opportunity is now closed.

CBCRP, along with the other statewide funding programs of the University of California Office of the President (UCOP) Research Grants Program Office (RGPO) and the Type 1 Diabetes Research Fund, are together making available up to $2M to immediately support urgent research to mitigate the COVID-19 pandemic.

Brief project proposals for a maximum of $25,000 direct costs and 6 months duration will be evaluated based on the potential to (a) generate rigorous, actionable science by qualified teams with essential infrastructure support; (b) yield measurable, short-term outcomes that, when taken to scale, can help blunt the impact of the COVID-19 outbreak; (c) address the needs of vulnerable populations, including those with the co-morbid conditions of HIV infection, COPD or other lung diseases, cardiovascular disease, diabetes, or cancer, as well as the medically underserved.

Projects will be reviewed on a rolling basis starting immediately and continuing until all available funds are expended. The project start date is immediately upon notification of award.

Learn more about the emergency RFP